Noked Israel Ltd Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Noked Israel Ltd raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 14.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 3,285,359 shares of the company's stock after acquiring an additional 418,006 shares during the period. Teva Pharmaceutical Industries comprises 14.3% of Noked Israel Ltd's portfolio, making the stock its 3rd biggest position. Noked Israel Ltd owned about 0.29% of Teva Pharmaceutical Industries worth $72,409,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Oarsman Capital Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $44,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $66,000. IFP Advisors Inc lifted its stake in Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in Teva Pharmaceutical Industries by 27.7% in the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after acquiring an additional 949 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.08 during midday trading on Friday, reaching $16.95. The stock had a trading volume of 9,758,609 shares, compared to its average volume of 9,995,809. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The firm has a 50 day simple moving average of $15.34 and a 200-day simple moving average of $17.43. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a market cap of $19.22 billion, a PE ratio of -11.69, a P/E/G ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter in the prior year, the business earned $0.48 EPS. The firm's revenue for the quarter was up 1.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Bank of America upped their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Finally, Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $24.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.